Hai Qian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hai Qian has a total of 475 co-authors. Here are the top co-authors by number of shared publications:
- Wenlong Huang
Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, Jiangsu, 210009, China
59 shared publications Wei Shi
Center of Drug Discovery, State Key Laboratory of Natural Medicines
43 shared publicationsQianqian Qiu
Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, P.R. China
39 shared publicationsWenlong Huang
Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, People’s Republic of China
33 shared publicationsChunxia Liu
Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, PR China; Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou University, Zhengzhou 450052, PR China
27 shared publicationsYuxuan Dai
Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, PR China; Shaanxi Key Laboratory of Brain Disorders & Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an, Shaanxi, 710021, PR China
25 shared publications
Latest Publications
- 14 October 2026
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23 (11) , 5946-5955
Preclinical Study of the 89Zr/177Lu-Labeled Engineered VHH-based Antibody for CLDN18.2-Targeted Radiotheranostics
Claudin 18.2 (CLDN18.2) is a tight junction protein aberrantly expressed in gastric and pancreatic cancer. In this study, we developed the novel nanobody 18.2−50H and VHH-Fc fusion antibody 18.2−50C radiolabeled with 89Zr/177Lu for CLDN18.2-targeted radiotheranostics. Zolbetuximab (IMAB362), 18.2−50H, and 18.2−50C were conjugated with DFO and labeled with 89Zr, respectively. Radiochemical purity and in vitro stability were determined by radio-TLC. CLDN18.2-targeting specificity was evaluated using HEK-293T and HEK-293T/CLDN18.2 cells. PET/CT imaging and biodistribution studies were performed in mouse models and cynomolgus monkeys. Subsequently, 177Lu-DOTA-18.2-50C was prepared and assessed for tumor targeting in gastric cancer PDX models. 89Zr-DFO-IMAB362, 89Zr-DFO-18.2-50H, and 89Zr-DFO-18.2-50C were prepared with satisfactory radiochemical yield, specific activity, and stability. Tumors were clearly visible as early as 1 h post-injection of 89Zr-DFO-18.2-50H, with an uptake value of 9.07 ± 2.36 %ID/g and a tumor-to-muscle ratio of 27.35 ± 3.72. Fc-fused 89Zr-DFO-18.2-50C exhibited improved retention and higher tumor uptake than 89Zr-DFO-18.2-50H and 89Zr-DFO-IMAB362, with % ID/g increasing continuously from 5.07 ± 0.29 at 1 h to 32.95 ± 1.57 at 168 h. Notably, the introduction of the Fc chain also markedly increased the radiation exposure in the liver and spleen. Consistently, PET imaging in cynomolgus showed that 89Zr-DFO-18.2-50C is mainly concentrated in the liver, but no apparent abnormality was observed. Furthermore, 177Lu-DOTA-18.2-50C presented remarkable tumor selectivity with prolonged retention (16.92 ± 1.94 % ID/g at 5 d post-injection) in PDX models. Nanobody 89Zr-DFO-18.2-50H demonstrated a superior tumor-to-background ratio, positioning it as a promising tracer for detecting CLDN18.2-overexpressing lesions. 89Zr/177Lu-labeled VHH-Fc antibody 18.2−50C exhibited sustained higher tumor uptake than commercially available IMAB362 and provides a novel potential candidate for CLDN18.2-targeted radionuclide therapy.
- 14 October 2026
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23 (11) , 5946-5955
Preclinical Study of the 89Zr/177Lu-Labeled Engineered VHH-based Antibody for CLDN18.2-Targeted Radiotheranostics
Claudin 18.2 (CLDN18.2) is a tight junction protein aberrantly expressed in gastric and pancreatic cancer. In this study, we developed the novel nanobody 18.2−50H and VHH-Fc fusion antibody 18.2−50C radiolabeled with 89Zr/177Lu for CLDN18.2-targeted radiotheranostics. Zolbetuximab (IMAB362), 18.2−50H, and 18.2−50C were conjugated with DFO and labeled with 89Zr, respectively. Radiochemical purity and in vitro stability were determined by radio-TLC. CLDN18.2-targeting specificity was evaluated using HEK-293T and HEK-293T/CLDN18.2 cells. PET/CT imaging and biodistribution studies were performed in mouse models and cynomolgus monkeys. Subsequently, 177Lu-DOTA-18.2-50C was prepared and assessed for tumor targeting in gastric cancer PDX models. 89Zr-DFO-IMAB362, 89Zr-DFO-18.2-50H, and 89Zr-DFO-18.2-50C were prepared with satisfactory radiochemical yield, specific activity, and stability. Tumors were clearly visible as early as 1 h post-injection of 89Zr-DFO-18.2-50H, with an uptake value of 9.07 ± 2.36 %ID/g and a tumor-to-muscle ratio of 27.35 ± 3.72. Fc-fused 89Zr-DFO-18.2-50C exhibited improved retention and higher tumor uptake than 89Zr-DFO-18.2-50H and 89Zr-DFO-IMAB362, with % ID/g increasing continuously from 5.07 ± 0.29 at 1 h to 32.95 ± 1.57 at 168 h. Notably, the introduction of the Fc chain also markedly increased the radiation exposure in the liver and spleen. Consistently, PET imaging in cynomolgus showed that 89Zr-DFO-18.2-50C is mainly concentrated in the liver, but no apparent abnormality was observed. Furthermore, 177Lu-DOTA-18.2-50C presented remarkable tumor selectivity with prolonged retention (16.92 ± 1.94 % ID/g at 5 d post-injection) in PDX models. Nanobody 89Zr-DFO-18.2-50H demonstrated a superior tumor-to-background ratio, positioning it as a promising tracer for detecting CLDN18.2-overexpressing lesions. 89Zr/177Lu-labeled VHH-Fc antibody 18.2−50C exhibited sustained higher tumor uptake than commercially available IMAB362 and provides a novel potential candidate for CLDN18.2-targeted radionuclide therapy.
- 29 June 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (13) , 15961-15973
Selective Visualization of ROR1-Positive TNBC of the Mesenchymal-Like Subtype Using Peptide-Based 68 Ga-PET Radiotracers
Triple-negative breast cancer (TNBC) lacks effective molecular targets for imaging. Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is overexpressed in the mesenchymal-like (claudin-low) subtype of TNBC. Here, we developed two optimized linear peptide radiotracers, DR1 and DR2, derived from the complementarity-determining regions (CDR) of an anti-ROR1 antibody, conjugated with DOTA and labeled with 68Ga. Both peptides showed nanomolar binding affinities (KD = 93.4 ± 8.2 nM for DR1 and 38.0 ± 4.6 nM for DR2) and favorable target-binding properties. [68Ga]Ga-DOTA-DR2 exhibited excellent in vitro stability (≥95% radiochemical purity after 4 h in human serum), rapid in vivo clearance (t1/2β = 0.66 ± 0.11 h), and specific cellular uptake. Micro-PET/CT imaging in MDA-MB-231 xenograft mice revealed rapid tumor visualization, with a peak tumor uptake of 2.75 ± 0.61 %ID/g at 1 h and a tumor-to-muscle ratio of 7.98 at 2 h. Blocking studies confirmed ROR1-specific targeting. Collectively, [68Ga]Ga-DOTA-DR2 may represent a promising PET tracer for imaging ROR1-positive mesenchymal-like TNBC, providing a foundation for further optimization.
- 29 June 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (13) , 15961-15973
Selective Visualization of ROR1-Positive TNBC of the Mesenchymal-Like Subtype Using Peptide-Based 68 Ga-PET Radiotracers
Triple-negative breast cancer (TNBC) lacks effective molecular targets for imaging. Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is overexpressed in the mesenchymal-like (claudin-low) subtype of TNBC. Here, we developed two optimized linear peptide radiotracers, DR1 and DR2, derived from the complementarity-determining regions (CDR) of an anti-ROR1 antibody, conjugated with DOTA and labeled with 68Ga. Both peptides showed nanomolar binding affinities (KD = 93.4 ± 8.2 nM for DR1 and 38.0 ± 4.6 nM for DR2) and favorable target-binding properties. [68Ga]Ga-DOTA-DR2 exhibited excellent in vitro stability (≥95% radiochemical purity after 4 h in human serum), rapid in vivo clearance (t1/2β = 0.66 ± 0.11 h), and specific cellular uptake. Micro-PET/CT imaging in MDA-MB-231 xenograft mice revealed rapid tumor visualization, with a peak tumor uptake of 2.75 ± 0.61 %ID/g at 1 h and a tumor-to-muscle ratio of 7.98 at 2 h. Blocking studies confirmed ROR1-specific targeting. Collectively, [68Ga]Ga-DOTA-DR2 may represent a promising PET tracer for imaging ROR1-positive mesenchymal-like TNBC, providing a foundation for further optimization.
- 23 April 2026
- Published by American Chemical Society (ACS) in Journal of Chemical Education
- Vol. 103 (5) , 2634-2640
An Experimental Design for Pharmacy Undergraduates: Applying Conductometric Methods to Study the Kinetics of Aspirin Alkaline Hydrolysis
- 23 April 2026
- Published by American Chemical Society (ACS) in Journal of Chemical Education
- Vol. 103 (5) , 2634-2640
An Experimental Design for Pharmacy Undergraduates: Applying Conductometric Methods to Study the Kinetics of Aspirin Alkaline Hydrolysis
- 23 March 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (7) , 8628-8639
Peptide-Based ROR1-Targeting PET Ligands for Melanoma Tumor Imaging: Design and Preclinical Evaluation
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is overexpressed in multiple cancers while remaining largely absent in adult tissues, which makes it an attractive target for both tumor diagnosis and therapy. To enable noninvasive imaging of ROR1, four peptide-based PET ligands [68Ga]1–4 were rationally designed and evaluated for melanoma imaging. In vitro assays confirmed reasonable ROR1 binding affinity (KD = 481.0 and 44.9 nM, respectively) and specific cellular uptake of [68Ga]2 and [68Ga]3, which are functionalized with serum albumin-binding groups. Notably, microPET/CT imaging and biodistribution studies in B16F10, A375, and SK-MEL-28 tumor-bearing mice demonstrated that [68Ga]2 achieved the most favorable imaging performance, characterized by high tumor accumulation (up to 9.18% ID/g), sustained retention, and a relatively lower nonspecific background signal. These findings highlight [68Ga]2 as a promising candidate for ROR1-targeting PET imaging and underscore the potential of peptide-based ROR1 PET probes for tumor imaging and therapy guidance.
- 23 March 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (7) , 8628-8639
Peptide-Based ROR1-Targeting PET Ligands for Melanoma Tumor Imaging: Design and Preclinical Evaluation
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is overexpressed in multiple cancers while remaining largely absent in adult tissues, which makes it an attractive target for both tumor diagnosis and therapy. To enable noninvasive imaging of ROR1, four peptide-based PET ligands [68Ga]1–4 were rationally designed and evaluated for melanoma imaging. In vitro assays confirmed reasonable ROR1 binding affinity (KD = 481.0 and 44.9 nM, respectively) and specific cellular uptake of [68Ga]2 and [68Ga]3, which are functionalized with serum albumin-binding groups. Notably, microPET/CT imaging and biodistribution studies in B16F10, A375, and SK-MEL-28 tumor-bearing mice demonstrated that [68Ga]2 achieved the most favorable imaging performance, characterized by high tumor accumulation (up to 9.18% ID/g), sustained retention, and a relatively lower nonspecific background signal. These findings highlight [68Ga]2 as a promising candidate for ROR1-targeting PET imaging and underscore the potential of peptide-based ROR1 PET probes for tumor imaging and therapy guidance.
- Open Access
- 11 December 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 390, 114536
A dual-responsive AI-designed peptide P9-conjugate disrupts E6–E6AP Interface to restore p53 and suppress HPV16-driven cervical cancer
- 11 December 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 390, 114536
Open AccessA dual-responsive AI-designed peptide P9-conjugate disrupts E6–E6AP Interface to restore p53 and suppress HPV16-driven cervical cancer
- 10 November 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (22) , 24579-24602
Discovery of Novel Potent and Safe Immunoproteasome Inhibitors with Bridged Ring for Anti-Inflammatory Therapy
Current clinical proteasome inhibitors suffer from nonselective pan-inhibition, leading to severe toxicity. Selective immunoproteasome inhibition offers a safer therapeutic strategy for autoimmune diseases. However, the inadequate LMP7/β5 selectivity of existing immunoproteasome inhibitors still lead to potential clinical side effects. To overcome this limitation, we designed and synthesized a series of novel immunoproteasome inhibitors featuring a bridged ring. The optimal compound A33 exhibited potent LMP7 inhibitory activity with >100-fold selectivity over β5 at the cellular level, along with ancillary activity against LMP2/MECL-1. Remarkably, A33 showed excellent anti-inflammatory effects in a mouse model of arthritis, and a favorable safety profile in toxicological studies, with reduced hepatotoxicity and hematotoxicity. Critically, we established a direct correlation between high LMP7/β5 selectivity and diminished systemic toxicity. In addition, A33 had favorable pharmacokinetic characteristics both in vitro and in vivo. These attractive drug-like properties establish A33 as a promising preclinical candidate compound with optimized selectivity and improved safety profile that merit further investigation.
- 10 November 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (22) , 24579-24602
Discovery of Novel Potent and Safe Immunoproteasome Inhibitors with Bridged Ring for Anti-Inflammatory Therapy
Current clinical proteasome inhibitors suffer from nonselective pan-inhibition, leading to severe toxicity. Selective immunoproteasome inhibition offers a safer therapeutic strategy for autoimmune diseases. However, the inadequate LMP7/β5 selectivity of existing immunoproteasome inhibitors still lead to potential clinical side effects. To overcome this limitation, we designed and synthesized a series of novel immunoproteasome inhibitors featuring a bridged ring. The optimal compound A33 exhibited potent LMP7 inhibitory activity with >100-fold selectivity over β5 at the cellular level, along with ancillary activity against LMP2/MECL-1. Remarkably, A33 showed excellent anti-inflammatory effects in a mouse model of arthritis, and a favorable safety profile in toxicological studies, with reduced hepatotoxicity and hematotoxicity. Critically, we established a direct correlation between high LMP7/β5 selectivity and diminished systemic toxicity. In addition, A33 had favorable pharmacokinetic characteristics both in vitro and in vivo. These attractive drug-like properties establish A33 as a promising preclinical candidate compound with optimized selectivity and improved safety profile that merit further investigation.
- 9 November 2025
- Published by Wiley in Medicinal Research Reviews
- Vol. 46 (3) , 561-584
The Evolution of Benzodiazepine Allosteric Modulators: Structural Insights From Historical Milestones to Emerging Innovations in Drug Discovery and Development
Benzodiazepine drugs (BZDs) have been central to neuropsychopharmacology since the 1960s, acting as positive allosteric modulators of γ‐aminobutyric acid type A (GABA A ) receptors to enhance inhibitory neurotransmission. Despite their clinical efficacy, long‐term use is limited by tolerance, dependence, and cognitive side effects. This review summarizes the structural evolution of BZD modulators, with a focus on subtype‐selective interactions with GABA A receptor isoforms. Advances in cryo‐electron microscopy and AI‐driven modeling have clarified the architecture and pharmacological roles of distinct receptor subunits, enabling the design of ligands that dissociate therapeutic effects from adverse outcomes. We also highlight the development of nonclassical scaffolds—such as imidazopyridines, triazolopyridazines, and cinnolines—which improve metabolic stability and subtype specificity. In addition, emerging formulation technologies and novel indications, including chronic pain, asthma, and neurodegenerative disorders, broaden the therapeutic scope of BZD‐related compounds. Collectively, these advances underscore a shift toward rational, structure‐based design of next‐generation BZD receptor modulators with improved efficacy, safety, and clinical precision.
- 9 November 2025
- Published by Wiley in Medicinal Research Reviews
- Vol. 46 (3) , 561-584
The Evolution of Benzodiazepine Allosteric Modulators: Structural Insights From Historical Milestones to Emerging Innovations in Drug Discovery and Development
Benzodiazepine drugs (BZDs) have been central to neuropsychopharmacology since the 1960s, acting as positive allosteric modulators of γ‐aminobutyric acid type A (GABA A ) receptors to enhance inhibitory neurotransmission. Despite their clinical efficacy, long‐term use is limited by tolerance, dependence, and cognitive side effects. This review summarizes the structural evolution of BZD modulators, with a focus on subtype‐selective interactions with GABA A receptor isoforms. Advances in cryo‐electron microscopy and AI‐driven modeling have clarified the architecture and pharmacological roles of distinct receptor subunits, enabling the design of ligands that dissociate therapeutic effects from adverse outcomes. We also highlight the development of nonclassical scaffolds—such as imidazopyridines, triazolopyridazines, and cinnolines—which improve metabolic stability and subtype specificity. In addition, emerging formulation technologies and novel indications, including chronic pain, asthma, and neurodegenerative disorders, broaden the therapeutic scope of BZD‐related compounds. Collectively, these advances underscore a shift toward rational, structure‐based design of next‐generation BZD receptor modulators with improved efficacy, safety, and clinical precision.
- 13 October 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (20) , 20857-20858
Call for Papers: Pharmaceutical Innovation and Global Health: Breakthroughs and Future─Celebrating the 90th Anniversary of China Pharmaceutical University
- 13 October 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (20) , 20857-20858
Call for Papers: Pharmaceutical Innovation and Global Health: Breakthroughs and Future─Celebrating the 90th Anniversary of China Pharmaceutical University
- 13 August 2025
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 17 (34) , 47857-47868
Enzyme-Responsive Peptide-Prodrug Integrated Biphasic Microneedle Patch for Enhanced Transdermal Delivery and Hypertension Therapy
Hypertension is a major risk factor for cardiovascular diseases and needs effective blood pressure reduction. Current antihypertensive drugs, such as captopril, face challenges, including the enzymatic degradation and the liver first-pass effect. Here, we developed a dissolving microneedle (MN) loaded with a peptide-based enzyme-responsive prodrug peptide-captopril (PC) to enhance the stability of captopril and enable efficient transdermal delivery. Kinetic studies revealed that PC exhibited a lower Km value (1.1 × 10-5 M) for esterase-mediated hydrolysis compared to free captopril (2.1 × 10-5 M), indicating improved enzymatic stability. Meanwhile, PC was encapsulated stably in microneedle tips to form the PC MN, achieving approximately 90% transdermal drug delivery. In spontaneously hypertensive rat models, PC MN elicited a rapid and potent blood-pressure-lowering effect, outperforming oral captopril administration. This study presents a promising self-administering strategy to enhance hypertension treatment through efficient transdermal drug delivery.
- 13 August 2025
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 17 (34) , 47857-47868
Enzyme-Responsive Peptide-Prodrug Integrated Biphasic Microneedle Patch for Enhanced Transdermal Delivery and Hypertension Therapy
Hypertension is a major risk factor for cardiovascular diseases and needs effective blood pressure reduction. Current antihypertensive drugs, such as captopril, face challenges, including the enzymatic degradation and the liver first-pass effect. Here, we developed a dissolving microneedle (MN) loaded with a peptide-based enzyme-responsive prodrug peptide-captopril (PC) to enhance the stability of captopril and enable efficient transdermal delivery. Kinetic studies revealed that PC exhibited a lower Km value (1.1 × 10-5 M) for esterase-mediated hydrolysis compared to free captopril (2.1 × 10-5 M), indicating improved enzymatic stability. Meanwhile, PC was encapsulated stably in microneedle tips to form the PC MN, achieving approximately 90% transdermal drug delivery. In spontaneously hypertensive rat models, PC MN elicited a rapid and potent blood-pressure-lowering effect, outperforming oral captopril administration. This study presents a promising self-administering strategy to enhance hypertension treatment through efficient transdermal drug delivery.